Sun Pharma Advanced Research Company Limited (SPARC) - Total Liabilities
Based on the latest financial reports, Sun Pharma Advanced Research Company Limited (SPARC) has total liabilities worth Rs6.67 Billion INR (≈ $72.14 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Sun Pharma Advanced Research Company Lim (SPARC) investment intensity to see how much of total assets are deployed in long-term investments.
Sun Pharma Advanced Research Company Limited - Total Liabilities Trend (2007–2025)
This chart illustrates how Sun Pharma Advanced Research Company Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Sun Pharma Advanced Research Company Lim.
Sun Pharma Advanced Research Company Limited Competitors by Total Liabilities
The table below lists competitors of Sun Pharma Advanced Research Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chin Hung Int'
KO:002780
|
Korea | ₩322.19 Billion |
|
Danel (Adir Yeoshua) Ltd
TA:DANE
|
Israel | ILA907.58 Million |
|
Turkiye Sinai Kalkinma Bankasi AS
IS:TSKB
|
Turkey | TL251.26 Billion |
|
Cogobuy Group
F:7C3
|
Germany | €6.18 Billion |
|
Hemnet Group AB
ST:HEM
|
Sweden | Skr1.14 Billion |
|
YaGuang Technology Group Co Ltd
SHE:300123
|
China | CN¥3.25 Billion |
|
Inly Media Co Ltd
SHG:603598
|
China | CN¥2.18 Billion |
|
Israel Shipyards Ltd
TA:ISHI
|
Israel | ILA1.05 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Sun Pharma Advanced Research Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SPARC equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sun Pharma Advanced Research Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sun Pharma Advanced Research Company Limited (2007–2025)
The table below shows the annual total liabilities of Sun Pharma Advanced Research Company Limited from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs5.52 Billion ≈ $59.75 Million |
+41.92% |
| 2024-03-31 | Rs3.89 Billion ≈ $42.10 Million |
+22.67% |
| 2023-03-31 | Rs3.17 Billion ≈ $34.32 Million |
+27.52% |
| 2022-03-31 | Rs2.49 Billion ≈ $26.91 Million |
-37.46% |
| 2021-03-31 | Rs3.98 Billion ≈ $43.04 Million |
+36.65% |
| 2020-03-31 | Rs2.91 Billion ≈ $31.49 Million |
+184.82% |
| 2019-03-31 | Rs1.02 Billion ≈ $11.06 Million |
-17.61% |
| 2018-03-31 | Rs1.24 Billion ≈ $13.42 Million |
+8.48% |
| 2017-03-31 | Rs1.14 Billion ≈ $12.37 Million |
-13.84% |
| 2016-03-31 | Rs1.33 Billion ≈ $14.36 Million |
+209.67% |
| 2015-03-31 | Rs428.71 Million ≈ $4.64 Million |
-3.09% |
| 2014-03-31 | Rs442.40 Million ≈ $4.78 Million |
-56.01% |
| 2013-03-31 | Rs1.01 Billion ≈ $10.88 Million |
-33.94% |
| 2012-03-31 | Rs1.52 Billion ≈ $16.46 Million |
+111.81% |
| 2011-03-31 | Rs718.75 Million ≈ $7.77 Million |
+23.68% |
| 2010-03-31 | Rs581.15 Million ≈ $6.28 Million |
+124.60% |
| 2009-03-31 | Rs258.75 Million ≈ $2.80 Million |
+55.03% |
| 2008-03-31 | Rs166.91 Million ≈ $1.81 Million |
+200.36% |
| 2007-03-31 | Rs55.57 Million ≈ $600.96K |
-- |
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia th… Read more